# Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma

> **NCT00102024** · PHASE1,PHASE2 · TERMINATED · sponsor: **Biogen** · enrollment: 30 (—)

## Conditions studied

- Colorectal Cancer
- Metastases

## Interventions

- **DRUG:** Unconjugated IDEC-159
- **DRUG:** 111In-IDEC-159
- **DRUG:** 90Y-IDEC-159

## Key facts

- **NCT ID:** NCT00102024
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-01
- **Primary completion:** 2006-01
- **Final completion:** 2006-01
- **Target enrollment:** 30 (—)
- **Last updated:** 2010-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00102024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00102024, "Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00102024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*